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Background: Intensity-modulated radiation therapy (IMRT) has represented a technical milestone that has
facilitated the clinical implementation. The purpose of this study was to evaluate the prognostic value of maximum
primary tumor diameter (MPTD) in patients with nasopharyngeal carcinoma (NPC) treated using IMRT.
Methods: Five-hundred and sixty-six patients with non-metastatic, histologically-confirmed NPC were retrospectively
reviewed. MPTD was measured using magnetic resonance imaging (MRI). All patients were treated using IMRT; 87.5%
(456/521) of patients with Stage T3-T4/N1-N3 disease also received cisplatin-based chemotherapy. Receiver operating
characteristic (ROC) curves were used to identify the optimal MPTD cut-off point and examine the prognostic value of
combining MPTD with the current T classification criteria.
Results: Median follow-up for all patients was 36 months (range, 1–52 months). The 3-year overall survival (OS),
failure-free survival (FFS), distant metastasis-free survival (DMFS), and local relapse-free survival (LRFS) rates for
patients with a MPTD ≤41 vs. >41 mm were 96.1% vs. 85.4%, 93.7% vs. 74.7%, 96.1% vs. 79.7%, and 98.1% vs.
92.9%, respectively (all P < 0.05). In multivariate analysis, MPTD was an independent prognostic factor for OS, FFS,
DMFS and LRFS in all patients (all P < 0.05). Among stage T3-T4 patients, the 3-year OS, FFS, DMFS, and LRFS rates
for patients with a MPTD ≤41 vs. >41 mm were 96.9% vs. 84.5%, 95.4% vs. 73.5%, 96.1% vs. 79.2%, and 99.3% vs.
92.6%, respectively (all P < 0.05). In multivariate analysis, MPTD was also an independent prognostic factor for OS,
FFS and DMFS in stage T3-T4 patients (all P < 0.05), and the difference in LRFS was almost statistically significant
(P = 0.05). ROC curves verified that inclusion of MPTD improved the predictive value of the current T classification
criteria (P < 0.001).
Conclusions: MPTD was an independent prognostic factor in patients with NPC treated using IMRT, and
significantly improved the prognostic value of the current T classification criteria for NPC.
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Compared to other head and neck carcinomas, nasopha-
ryngeal carcinoma (NPC) has a number of unique char-
acteristics. Firstly, in contrast to its very low incidence in
most other regions of the world, there is a high inci-
dence of NPC in China and other countries in Southeast
Asia [1]. Secondly, keratinizing squamous cell carcinoma
is the major histological type in non-endemic areas;
however, more than 95% of cases in the endemic areas
are non-keratinizing carcinoma [2,3]. Thirdly, unlike other
head and neck cancers, NPC is closely associated with
Epstein-Barr viral infection [4,5]. Fourthly, radiotherapy
(RT) is the first choice and main treatment method for
non-metastatic NPC.
The introduction of intensity-modulated radiation
therapy (IMRT) in the late 20th century represented a
milestone in RT techniques. IMRT enables the tumor to
receive higher dose of radiation, provides a more con-
formal dose distribution than two-dimensional RT (2-
DRT) and significantly reduces the dose to surrounding
normal anatomical structures. Lee et al. initially reported
that the 4-year local progression free survival rate for
NPC after IMRT was 97% (in 67 patients, 70% of whom
had stage III-IV disease) [6]. Subsequently, other studies
have confirmed that IMRT leads to excellent local con-
trol in NPC [7,8].
The seventh edition of the American Joint Commit-
tee on Cancer (AJCC) staging system and the Chinese
2008 staging system for NPC are widely used in clinical
work [9,10]. The T classifications of both systems are
based on tumor invasion of anatomical structures and
cranial nerve paralysis, and do not include tumor size.
Primary gross tumor volume (GTV-P) is an important
prognostic factor in NPC [11,12]. However, assessment
of GTV-P is so time-consuming that it violates the
basic requirements for staging systems to be simple
and practical.
Liang et al. provided the first demonstration that
maximum primary tumor diameter (MPTD) was an
important prognostic factor for 5-year overall survival
(OS), failure-free survival (FFS), distant metastasis-free
survival (DMFS) and local relapse-free survival (LRFS)
in NPC [13]. However, the techniques employed in that
study have been replaced with superior techniques.
Firstly, the patients received 2-DRT or three-dimensional
conformal RT (3-DCRT) instead of IMRT, which not
only offers local control, but also reduces RT-related
toxicities in patients with NPC [14,15]. Secondly, the
addition of concurrent chemotherapy to radiotherapy
has improved the survival outcome of patients with
loco-regionally advanced NPC [16-18]; however, only
46.6% (131/281) of the patients with Stage III-IVB dis-
ease received concurrent chemoradiotherapy [13]. Fur-
thermore, it remains unknown whether the addition ofMPTD could improve the prognostic value of the T
classification system for NPC.
On the basis of this premise, we initiated a retrospect-
ive study of a large cohort of patients to evaluate the
prognostic value of MPTD in patients with NPC treated
by IMRT and to determine whether the prognostic value
of the current T classification system could be improved
when combined with assessment of MPTD.
Methods
Study population
The Institutional Review Board of the Sun Yat-sen
University Cancer Center approved the retrospective
study. Written consent was waived, while oral consent
was obtained via telephone and documented by tele-
phone recording.
If the participants were at the age of 18 or over it, the
oral consent was obtained from the participants.
Otherwise, it would be obtained from their parents or
guardians. Between November 2009 and December
2012, 566 consecutive patients with newly-diagnosed,
histologically-proven, non-metastatic NPC who were
treated at Sun Yat-sen University Cancer Center were
included in this retrospective study. The cohort in-
cluded 415 males and 151 females (male:female ratio,
2.7:1) with a median age of 46 years (range, 14–80
years). Histologically, 99.8% (565/566) of patients had
non-keratinizing NPC; 0.2% (1/566) had keratinizing
NPC. All patients underwent a pretreatment evaluation
that included a complete medical history, physical and
neurological examinations, hematology and biochemis-
try profiles, MRI scan of the nasopharynx and neck,
chest radiography and abdominal sonography. Medical
and imaging records were retrospectively reviewed,
and all patients were restaged according to the 7th edi-
tion of the AJCC. The TNM stage distribution for all
patients was 25.8% for T1, 17.5% for T2, 39.4% for T3,
and 17.3% for T4; 16.1% for N0, 60.2% for N1, 20% for
N2, and 3.7% for N3; 5.8% for stage I, 27.9% for stage
II, 45.9% stage III, and 20.3% stage IVA-B.
Imaging protocol
All patients underwent MRI using a 1.5-Tesla system
(Signa CV/i; General Electric Healthcare, Chalfont St.
Giles, United Kingdom). The area from the suprasellar
cistern to the inferior margin of the sternal end of the
clavicle was examined using a head-and-neck combined
coil. T1-weighted fast spin-echo images in the axial, cor-
onal and sagittal planes (repetition time, 500–600 ms;
echo time, 10–20 ms; 22 cm field of view; 256 × 512 fre-
quency matrix), and T2-weighted fast spin-echo MRI in
the axial plane (repetition time, 4,000-6,000 ms; echo
time, 95–110 ms; 22 cm field of view; 256 × 512
frequency matrix) were obtained before injection of
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tetate dimeglumine (0.1 mmol/kg body weight Gd-DTPA;
Magnevist; Bayer-Schering, Berlin, Germany), spin-echo
T1-weighted axial and sagittal sequences and spin-echo
T1-weighted fat-suppressed coronal sequences were
performed sequentially, using similar parameters to be-
fore injection. The section thickness was 3–4 mm with
a 1 mm interslice gap for the sagittal plane, and 5 mm
with a 1 mm interslice gap for the coronal and axial
planes.
Image assessment
Two radiologists qualified in diagnostic imaging in
China with ≥10 years clinical experience focusing on
head and neck carcinoma evaluated the MR images
separately. Every two weeks, any disagreements were
resolved by consensus. Tumors and soft tissue had
intermediate signal intensity on pre-Gd-DTPA-T1 and
T2-weighted images and enhanced intensity on post-
Gd-DTPA T1-weighted images, with tumor replacing
the normal anatomy of the structure. MPTD, defined
as the maximum diameter of the continuous, uninter-
rupted tumor signal on post-Gd-DTPA T1-weighted
images, was measured in the axial, coronal and sagittal
planes; the largest value was recorded as the MPTD
[13,19].
Treatment
All patients were treated using IMRT; the protocol has
previously been reported in detail [20,21]. The pre-
scribed dose was 68–70 Gy to the planning target vol-
ume (PTV) of GTV-P, 60–66 Gy to the PTV of the
nodal gross tumor volume (GTV-N), 60–62 Gy to the
PTV of CTV-1 (i.e. high-risk regions) and 54–56 Gy to
the PTV of CTV-2 (i.e. low-risk regions and neck nodal
regions) over 30–31 fractions. RT was delivered over
one fraction daily, 5 days per week.
Based on institutional treatment guidelines, concurrent
chemotherapy was recommended for Stage T1-2N1M0
disease and concurrent chemotherapy +/− induction
chemotherapy or adjuvant chemotherapy for Stage III-IVb
disease. Overall, platinum-based chemotherapy was ad-
ministered to 87.5% (456/521) of patients with Stage
T1-2N1M0 or Stage III-IVb disease. In the event of
documented relapse or persistent disease, salvage treat-
ments including after-loading, surgery or chemotherapy
were provided when appropriate.
Follow up and statistical analysis
Patients were assessed every three months during the
first two years, and every six months thereafter until
censored (death, loss of follow-up or study termination).
With regards to the measured indices, OS was measured
from assignment to the date of death from any cause;FFS indicated the first failure at any site; and LRFS and
DMFS were recorded as the first local or remote failure,
respectively. Distant metastases were diagnosed based
on clinical symptoms, physical examinations and im-
aging methods including X-ray, bone scan, MRI, CT and
abdominal sonography. Locoregional recurrence was
established by fiberoptic endoscopy, biopsy and MRI.
All analyses were performed using SPSS software
version 13.0 (SPSS, Chicago, IL, USA). Actuarial rates
were calculated by the Kaplan-Meier method and the
differences were compared using the log-rank test.
Multivariate analyses with the Cox proportional haz-
ards model were used to test for significant independ-
ent prognostic factors using a backward elimination
strategy. All patients were randomly allocated to a
training set (n = 189) and a test set (n = 377). Receiver
operating characteristic (ROC) curve analysis was used
to evaluate different cut-off points for MPTD in the
training set. Then, the test set and all patients were strati-
fied according to the optimum cut-off point. The area
under the ROC curve was used to assess the prognostic
value of MPTD. The criterion for statistical significance
was set at α = 0.05 and P-values were based on two-sided
tests.
Results
Distribution of MPTD by T stage and survival rates
The distribution of MPTD by T stage is presented in
Figure 1. The median MPTD was 28.7 mm (range,
14–50 mm) in T1, 33.3 mm (17–65.3 mm) in T2,
39.7 mm in T3 (14.3-77.6 mm), and 59.6 mm in T4
(24–121.5 mm). The MPTD values varied widely within
the same T stage, and overlapped between different T
stages.
The median follow-up for all patients was 36 months
(range, 1 to 52 months). In total, 9% (51/566) of patients
developed distant metastases, 5.3% (30/566) developed
locoregional recurrence and 7.4% (42/566) died. The
3-year OS, DFS, DMFS and LRFS rates were 92.4%,
86.9%, 90.3% and 96.4%, respectively.
Identification and prognostic verification of the optimal
MPTD cut-off point
The optimal cut-off point for MPTD with respect to
OS in the training set (n = 189) was 41 mm (sensitivity
81.8%, specificity 66.9%; AUC [area under the ROC] =
0.74, P = 0.007). Therefore, we selected a uniform cut-
off point of 41 mm (>41 vs. ≤41 mm) to classify the test
set and all patients into high and low MPTD groups
for survival analysis.
In the test set (n = 377), the 3-year OS, FFS, and
DMFS rates for patients with a MPTD ≤41 vs. >41 mm
were 95.1% vs. 89.2%, 92.7% vs. 74.1%, and 95.5% vs.
77.9%, respectively (all P < 0.05). The 3-year LRFS rates
Figure 1 Distribution of maximum primary tumor diameter by T stage in 566 patients with NPC.
Chen et al. BMC Cancer  (2015) 15:305 Page 4 of 8for patients with a MPTD ≤41 vs. >41 mm were 98.1%
vs. 95.1% (P = 0.191).
Prognostic significance of MPTD in all patients
In all patients (n = 566), the 3-year OS, FFS, DMFS,
and LRFS rates for patients with a MPTD ≤41 vs.
>41 mm were 96.1% vs. 85.4% (P < 0.001), 93.7% vs.
74.7% (P < 0.001), 96.1% vs. 79.7% (P < 0.001), and
98.1% vs. 92.9% (P = 0.008), respectively (Figure 2). The
following parameters were included in the Cox propor-
tional hazards model: age (≤45 vs. >45 years), sex,
chemotherapy (yes vs. no) and additional boosts (yes
vs. no), T stage (T1-2 vs. T3-4), N stage (N0-1 vs. N2-3)
and MPTD (≤41 vs. >41 mm). MPTD was an inde-
pendent prognostic factor for OS, FFS, DMFS and
LRFS (all P < 0.05; Table 1).
Prognostic significance of MPTD in patients with advanced
T classification
The 321 patients with T3-T4 stage disease were divided
into two subgroups: Group 1 (T3-T4 disease with a
MPTD ≤41 mm) and Group 2 (T3-T4 disease with a
MPTD >41 mm). The 3-year OS, FFS, DMFS, and LRFS
rates of the patients in Group 1 and Group 2 were 96.9%
vs. 84.5% (P < 0.001), 95.4% vs. 73.5% (P < 0.001), 96.1% vs.
79.2% (P < 0.001), and 99.3% vs. 92.6% (P = 0.037; Figure 3).
The following parameters were included in the Cox
proportional hazards model: age (≤45 vs. >45 years),
sex, chemotherapy (yes vs. no), additional boosts (yes
vs. no), T stage (T3 vs. T4), N stage (N0-1 vs. N2-3)
and MPTD (≤41 vs. >41 mm). MPTD was an inde-
pendent prognostic factor for OS, FFS and DMFS (allP < 0.05), and the difference between LRFS was almost
statistically significant (P = 0.05; Table 2).
Predictive value of T classification combined with MPTD
vs. T classification alone
ROC curves were used to compare the predictive value
of T classification combined with MPTD vs. T classifica-
tion alone. In all patients, the AUC for T classification
combined with MPTD (<41 and >41 mm) was 0.70,
compared to 0.67 for T classification alone (P < 0.001;
Figure 4). These results indicate that T classification
combined with MPTD is superior to T classification
alone for predicting prognosis.
Discussion
IMRT has gradually replaced 2-DRT and 3-DCRT, and is
currently the mainstream radiotherapy technique. As a
result of the improved treatment outcomes provided in
NPC by IMRT, it is necessary to reassess the prognostic
factors identified by analyses of patients treated with 2-
DRT and 3-DCRT [3,22,23]. This study demonstrates
that MPTD was an independent prognostic factor for
OS, FFS, DMFS and LRFS in patients with NPC treated
using IMRT. Combining MPTD with the current criteria
significantly improved the prognostic value of the T clas-
sification system for NPC.
Prognostic value of MPTD in patients with NPC treated by
IMRT
Larger MPTD values were more frequent in patients
with higher T stage. However, the MPTD values varied
widely within the same T stage, and overlapped between
Figure 2 Survival rates of 566 patients with NPC stratified by maximum primary tumor Diameter. A. overall survival. B. failure-free survival. C. dis-
tant metastasis-free survival. D. local relapse-free survival. Abbreviations: 95% CI, 95% confidence interval; HR, hazard ratio; No at risk, number
at risk.
Table 1 Multivariate analyses of prognostic factors in 566
patients with nasopharyngeal carcinoma
Endpoint Variable HR 95% CI P-value
Overall survival MPTD 4.300 2.233-8.279 <0.001
Failure-free survival MPTD 3.968 2.402-6.559 <0.001
N stage 1.802 1.111-2.923 0.017
Distant metastasis-free survival MPTD 5.153 2.729-9.729 <0.001
N stage 2.329 1.334-4.064 0.003
Local relapse-free survival MPTD 3.277 1.355-7.927 0.008
Abbreviations: MPTD, maximum primary tumor diameter; 95% CI, 95%
confidence interval; HR, hazard ratio.
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a previous study [13], and indicate that the current T
classification does not accurately reflect tumor size in
patients with NPC.
In the previous study by Liang et al., the patients were
divided into three groups (≤30 vs. >30-50 vs. >50 mm)
on the basis of the balance of the distribution of the
MPTD values [13]. However, the ROC curve analysis
was used to define the optimal cut-off points in this
study. A MPTD cut-off point of 41 mm was selected for
predicting OS. This cut-off point was validated in the
test set, in which the 3-year OS, FFS and DMFS rates
Figure 3 Survival rates of 321 patients with T3-T4 stage NPC stratified by maximum primary tumor diameter. A. overall survival. B. failure-free sur-
vival. C. distant metastasis-free survival. D. local relapse-free survival. Abbreviations: 95% CI, 95% confidence interval; HR, hazard ratio; No at risk,
number at risk.
Table 2 Multivariate analyses of prognostic factors in 321
patients with nasopharyngeal carcinoma and advanced T
classification
Endpoint Variable HR 95% CI P-value
Overall survival MPTD 5.989 2.097-17.106 0.001
Failure-free survival MPTD 4.592 2.149-9.816 <0.001
N stage 1.797 1.031-3.131 0.039
Distant metastasis-free survival MPTD 5.266 2.048-13.541 <0.001
N stage 2.237 1.193-4.194 0.012
Local relapse-free survival MPTD 3.565 0.999-12.717 0.050
Abbreviations: MPTD, maximum primary tumor diameter; 95% CI, 95%
confidence interval; HR, hazard ratio.
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ter than those of patients with a MPTD >41 mm (all
P < 0.05).
MPTD (>41 vs. ≤41 mm) was an independent prog-
nostic factor for OS, FFS, DMFS and LRFS in both uni-
variate and multivariate analysis in all patients treated
using IMRT. Liang et al. previously reported that MPTD
(≤30 vs. >30-50 vs. >50 mm) was also an independent
prognostic factor for OS, FFS, DMFS and LRFS in pa-
tients with NPC treated using 2-DRT or 3-DCRT
[13]. Larger tumors may contain higher numbers of
clonogenic tumor cells, possess larger areas of tumor
hypoxia that promote resistance to radiotherapy and
Figure 4 Receiver operator characteristic (ROC) curves for all patients
with NPC (n = 566) when stratified by T classification combined
with maximum primary tumor diameter (MPTD) and by T
classification alone.
Chen et al. BMC Cancer  (2015) 15:305 Page 7 of 8chemotherapy, or be associated with increased risk of
distant micrometastases [24].
Prognostic value of adding MPTD to the current T
classification
In the stratified analysis of patients with stage T3-T4 dis-
ease, MPTD was an independent prognostic factor for
OS, FFS and DMFS (all P < 0.05), and the difference in
LRFS was nearly statistically significant (P = 0.05). Simi-
lar results were also observed in patients with NPC
treated using 2-DRT or 3-DCRT [13]. This indicates that
although advanced T classification disease is usually as-
sociated with poorer local control and shorter survival,
patients within the same T classification with different
MPTD values may have a different prognosis.
The current T classification does not include an as-
sessment of tumor size, which this study demonstrates is
an important prognostic factor in patients with NPC.
Compared to the previous study by Liang et al., in
addition to employing ROC curves analysis, we also in-
vestigated whether the prognostic value of the current T
classification could be improved by adding MPTD. This
study demonstrates that including MPTD in the current
T classification enables superior prognostication com-
pared to T classification alone (P < 0.001).
Comparison of MPTD with GTV-P
In 1997, Chua et al. reported that GTV-P values varied
widely within each T stage and represented an inde-
pendent prognostic factor for local control in NPC,
which appeared to be more predictive than Ho’s T stage
classification [11]. Subsequently, a number of studies
confirmed that GTV-P was an important prognostic fac-
tor in NPC [12,25,26]. Guo et al. reevaluated the prog-
nostic value of GTV-P in 694 patients with NPC treatedby IMRT, and confirmed that GTV-P was an independ-
ent prognostic factor that significantly improved the
prognostic validity of T stage system [27].
MPTD and GTV-P, indexes reflecting the primary
tumor size, are both important prognostic factors in
patients with NPC. Compared to GTV-P, MPTD pro-
vides a less accurate assessment of tumor size; however,
MPTD is quicker and easier to measure. Therefore,
MPTD may be more convenient in clinical work and
suitable for incorporation into the TNM staging system.
To the best of our knowledge, this is the first study to
investigate the prognostic value of MPTD in patients
with NPC treated by IMRT in a large number of pa-
tients. These results may help to refine the current T
staging system for NPC. However, this was a retrospect-
ive study based on single-institution data, which needs
to be confirmed by further multicentre studies.Conclusions
This study is the first attempt to evaluate the prognostic
value of MPTD in patients with NPC treated by IMRT.
Our analyses demonstrate that MPTD is also an inde-
pendent prognostic factor for OS, FFS, DMFS and LRFS
in patients with NPC treated by IMRT. Addition of
MPTD may help to refine the prognostic value of the
current staging system for NPC and assist with treatment
strategy selection.
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